Ali Banaie, MD
Gastroenterology · La Mesa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Offices
- 7
- Since medical school
- 28 years
- Graduated 1998
Offices
7 locations · Emergency and Acute Care Medical Corporation · Banaie Medical Corporation · Providence Medical Foundation
Hospitals listed: Grossmont Hospital · Providence Queen of the Valley Medical Center · Sharp Chula Vista Medical Center · Sharp Memorial Hospital · St Mary Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Banaie’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A87308 · Current
Licensed to practise in California · since 2004 · expires 2027-08-31 · St. George'S University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Grossmont Surgery Center - SCAAmbulatory Surgery Center · La Mesa, CAOwner · accredited by JCAccreditation Renewed4 inspections, 3 with deficiencies · last 2016-07-21: Requirements Met
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Grossmont HospitalLa Mesa, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of Sharp Healthcare, which runs 6 hospitalsPatients rate it 3 of 5 · 69% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.42, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.405, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.402, Oct 2024 – Sep 2025
- Providence Queen of the Valley Medical CenterNapa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.107, Oct 2024 – Sep 2025
- Sharp Chula Vista Medical CenterChula Vista, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of Sharp Healthcare, which runs 6 hospitalsPatients rate it 3 of 5 · 72% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.283, Oct 2024 – Sep 2025
- Sharp Memorial HospitalSan Diego, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sharp Healthcare, which runs 6 hospitalsPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Pressure ulcer rate: 1.41 (0.88 to 1.95) · 7,340 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.498, Oct 2024 – Sep 2025
- St Mary Medical CenterLong Beach, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 2 of 5 · 62% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.287, Oct 2024 – Sep 2025
See every measure and the patient survey for Grossmont Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 5 better, 2 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.42 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.405 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.402 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0.03 to 1.87) · 1,794 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.22 (0.93 to 1.51) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 178.41 (138.56 to 218.26) · 130 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.6 · 65 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.9 · 241 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.5 · 182 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.2 · 541 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 696 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.5 · 565 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 5,543 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.03 to 0.4) · 11,498 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.18 (0 to 0.36) · 11,909 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.9 (1 to 4.81) · 2,033 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.7 (0.16 to 3.24) · 594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (0.71 to 3.44) · 1,940 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.67 (7.88 to 21.46) · 587 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.04 (1.4 to 8.69) · 568 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.11 to 2.98) · 484 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.11 (0.61 to 1.6) · 9,450 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 94 cases | None | Apr 2023 – Mar 2025 |
| MRSA BacteremiaInfections | 0.767 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.204 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 298 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.8 · 979 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 12.1 · 191 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 14.3 · 652 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 22.8 · 757 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.4 · 1,071 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.6 (3 to 6.9) · 99 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (7 to 13.7) · 99 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 103 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.2 · 83 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 415 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10.5 to 17.5) · 981 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 407 cases | No different | Jan 2024 – Dec 2024 |
What patients said (3,466 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 69% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Providence Queen of the Valley Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.107 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.92) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.5 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 191.43 (130.54 to 252.33) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 271 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 175 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.41) · 4,152 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,188 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.81 (1.63 to 5.99) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.62 to 3.77) · 742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.45 (0.91 to 16) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.58 (1.75 to 9.42) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 152 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.94) · 2,994 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.684 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.887 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 270 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.1 · 316 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -1 · 399 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.4 · 337 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.5 to 7.8) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (9.8 to 17.7) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.2) · 848 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 423 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for Sharp Chula Vista Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 9 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.283 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.35 (0.36 to 2.34) · 872 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.12 (0.79 to 1.44) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 178.91 (128.64 to 229.19) · 68 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.3 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.6 · 126 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 137 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.3 · 412 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.7 · 490 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.2 · 364 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 4,213 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.41) · 6,145 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 6,385 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.81 (1.63 to 6) · 1,111 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.31 (0.68 to 3.94) · 209 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.06 (0.54 to 3.59) · 958 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.99 (2.49 to 17.49) · 220 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.09 (2.08 to 10.1) · 212 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.18 to 3.17) · 200 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.76 (0.15 to 1.38) · 5,253 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.4 · 34 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.404 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.224 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.582 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 255 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.4 · 933 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.9 · 134 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -0.4 · 488 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 3.2 · 528 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 894 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5 (3.3 to 7.9) · 47 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.3 to 15.2) · 47 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 35 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.6 · 77 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 23.1 · 253 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (9.9 to 18.2) · 133 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 150 cases | No different | Jan 2024 – Dec 2024 |
What patients said (2,585 patients answered, 16% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 71% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 85% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 72% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Sharp Memorial Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 6 the same, 0 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 1.41 (0.88 to 1.95) · 7,340 cases | Worse | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.498 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.2 (0.34 to 2.06) · 1,904 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.19 (0.93 to 1.46) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 168.64 (124.64 to 212.63) · 111 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 139 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.1 · 149 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 451 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.2 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.3 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 5,777 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.3 (0.11 to 0.48) · 9,499 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.11 to 0.47) · 9,575 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.81 (1.02 to 4.61) · 2,561 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.15 (0 to 2.59) · 923 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (0.72 to 3.28) · 2,373 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.93 (5.57 to 16.3) · 974 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.33 (1.15 to 7.5) · 963 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.55 (0.12 to 2.99) · 619 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 111 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.591 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.732 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.162 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.349 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.495 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.2 · 346 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 992 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.7 · 532 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 6.6 · 584 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 995 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.2 (4.3 to 9) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (9.3 to 16.5) · 135 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.4 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 61 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 263 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.3 (10.2 to 17.2) · 1,001 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.3) · 636 cases | No different | Jan 2024 – Dec 2024 |
What patients said (5,623 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 78% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 58% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for St Mary Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 4 the same, 0 worse of 6 measures. Readmissions: 2 better, 3 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.287 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0 to 2) · 447 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1 (0.6 to 1.39) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 157.28 (101.7 to 212.85) · 31 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 104 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 129 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.5 · 163 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 1,282 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 2,406 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,539 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.24 (1.82 to 6.66) · 360 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 53 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.13 (0.47 to 3.79) · 354 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.37 (0 to 17.99) · 56 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.06 (0.79 to 9.33) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.72 (0.2 to 3.23) · 62 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.69 (0 to 1.46) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 34 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.676 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.303 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.421 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.9 · 159 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.2 · 269 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 29.9 · 85 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -47.9 · 111 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 10.1 · 139 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 257 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.5 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 28 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.1 · 124 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 44 cases | No different | Jan 2024 – Dec 2024 |
What patients said (464 patients answered, 9% of those asked)
| Cleanliness | 3 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 2 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 72% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 67% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 79% |
| Patients who gave a rating of "9" or "10" (high) | 64% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 65% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 77% |
| "Always" quiet at night | 41% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$171,415
Medicare paid this office $171,415 for 772 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 272 | $39,532 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 182 | $16,068 | $84 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 88 | $15,396 | $175 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 70 | $13,806 | $197 |
| Return visit (30+ min) | 117 | $12,058 | $90 |
See all 20 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 272 | $39,532 | $134 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 182 | $16,068 | $84 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 88 | $15,396 | $175 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 70 | $13,806 | $197 |
| Return visit (30+ min) | 117 | $12,058 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 102 | $11,178 | $62 |
| New patient visit (30+ min) | 146 | $10,643 | $73 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 62 | $6,767 | $106 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 25 | $5,328 | $213 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $4,567 | $152 |
| Biopsy of large bowel using a flexible endoscope | 36 | $3,760 | $104 |
| Short return visit (20+ min) | 50 | $3,461 | $68 |
| Insertion of stomach tube using a flexible endoscope | 20 | $3,089 | $154 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 27 | $2,462 | $91 |
| Exam of common bile and/or pancreatic duct using a flexible endoscope | 16 | $1,563 | $92 |
| New patient visit (45+ min) | 12 | $1,406 | $117 |
| Incision of pancreatic outlet using a flexible endoscope | 25 | $952 | $37 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 15 | $662 | $37 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 147 | $607 | $4 |
| Injection of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $227 | $21 |
Procedures Medicare counted
| Colonoscopy | 267 | More than 96% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 507 | More than 98% of doctors who do this |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 137 | 102 | 141 | 139 | 162 | 192 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 68 | 48 | 40 | 51 | 50 | 70 |
| Biopsy of large bowel using a flexible endoscope | 24 | 23 | 22 | 26 | 24 | 36 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | 25 | 11 | 19 | 29 | 27 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | 16 | – | 14 | 32 | 30 |
| Diagnostic exam of large bowel using a flexible endoscope | 52 | 22 | 19 | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
772 Original Medicare patients in 2024. Average age 74 · Under 65 8% · 85 and older 14% · Women 49% · Also on Medicaid 37% · Health risk score 2.04. Above the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 44% · Coronary heart disease 40% · Chronic kidney disease 39% · Heart failure 31% · Depression 30% · Atrial fibrillation 27% · COPD 23% · Cancer 18% · Dementia 17% · Stroke 15%.
The office billed $1,377,848, Medicare allowed $219,722 and paid $171,415; for 1,730 services of 57 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 772 | 1,730 | 74 | 2.04 | $1,377,848 | $171,415 |
| 2023 | 706 | 1,539 | 74 | 2.19 | $1,203,057 | $158,749 |
| 2022 | 531 | 1,155 | 74 | 1.57 | $897,992 | $112,665 |
| 2021 | 514 | 1,039 | 75 | 1.51 | $855,135 | $113,200 |
| 2020 | 499 | 1,055 | 75 | 1.79 | $861,745 | $117,823 |
| 2019 | 598 | 1,284 | 74 | 1.71 | $1,076,714 | $146,155 |
| 2018 | 705 | 1,626 | 74 | 1.89 | $679,551 | $179,897 |
| 2017 | 624 | 1,291 | 74 | 1.53 | $513,010 | $140,500 |
| 2016 | 580 | 1,413 | 74 | 1.61 | $538,326 | $154,273 |
| 2015 | 611 | 1,446 | 74 | 1.43 | $510,655 | $164,513 |
| 2014 | 484 | 1,173 | 74 | 1.46 | $415,911 | $135,818 |
| 2013 | 440 | 1,303 | 73 | 1.50 | $445,255 | $145,080 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 243 | $36,235 | $137 |
| Return visit (30+ min) | 156 | $16,646 | $90 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 160 | $13,201 | $81 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 63 | $11,431 | $181 |
| New patient visit (30+ min) | 161 | $11,406 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 87 | $9,495 | $63 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 50 | $9,328 | $187 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 57 | $6,197 | $107 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $5,015 | $157 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 12 | $4,378 | $365 |
| Insertion of stomach tube using a flexible endoscope | 26 | $4,330 | $155 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 21 | $3,580 | $149 |
| Biopsy of large bowel using a flexible endoscope | 24 | $3,154 | $131 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $2,697 | $93 |
| New patient visit (45+ min) | 21 | $2,599 | $124 |
| Short return visit (20+ min) | 24 | $1,871 | $72 |
| Removal of foreign bodies of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,307 | $87 |
| Incision of pancreatic outlet using a flexible endoscope | 14 | $383 | $27 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 90 | $380 | $4 |
2022: 17 services
| Return visit (30+ min) | 206 | $22,973 | $84 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $15,487 | $158 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 135 | $11,276 | $81 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 55 | $10,436 | $190 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 51 | $10,382 | $204 |
| New patient visit (30+ min) | 132 | $8,240 | $62 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 17 | $3,285 | $193 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 11 | $2,791 | $233 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 33 | $2,730 | $83 |
| Biopsy of large bowel using a flexible endoscope | 26 | $2,725 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,640 | $57 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $2,311 | $165 |
| New patient visit (45+ min) | 18 | $2,057 | $114 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,758 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,078 | $83 |
| Short return visit (20+ min) | 11 | $690 | $57 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 97 | $413 | $4 |
2021: 16 services
| Return visit (30+ min) | 170 | $18,761 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 86 | $15,199 | $163 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 71 | $13,882 | $196 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 135 | $12,262 | $87 |
| New patient visit (30+ min) | 168 | $10,612 | $63 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 40 | $7,537 | $188 |
| Biopsy of large bowel using a flexible endoscope | 22 | $3,259 | $148 |
| New patient visit (45+ min) | 28 | $3,080 | $110 |
| Diagnostic exam of large bowel using a flexible endoscope | 19 | $2,618 | $138 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 22 | $1,842 | $84 |
| Short return visit (20+ min) | 37 | $1,678 | $44 |
| Exam of common bile and/or pancreatic duct using a flexible endoscope | 12 | $1,388 | $99 |
| Incision of pancreatic outlet using a flexible endoscope | 14 | $959 | $64 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $933 | $85 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $920 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $808 | $58 |
2020: 19 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 115 | $20,186 | $168 |
| Return visit (30+ min) | 141 | $13,185 | $77 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 48 | $9,672 | $201 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 99 | $9,523 | $93 |
| Short return visit (20+ min) | 106 | $7,005 | $53 |
| New patient visit (30+ min) | 98 | $6,399 | $65 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 27 | $5,422 | $201 |
| Destruction of stone of bile or pancreatic duct using a flexible endoscope | 13 | $4,254 | $327 |
| New patient visit (45+ min) | 30 | $3,270 | $109 |
| Diagnostic exam of large bowel using a flexible endoscope | 22 | $3,178 | $144 |
| Biopsy of large bowel using a flexible endoscope | 23 | $2,883 | $125 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $2,489 | $156 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,466 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,612 | $115 |
| Exam of common bile and/or pancreatic duct using a flexible endoscope | 15 | $1,537 | $102 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,283 | $86 |
| Biopsy of small bowel (except ileum) using an endoscope | 12 | $1,073 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $782 | $60 |
| Incision of pancreatic outlet using a flexible endoscope | 17 | $499 | $29 |
2019: 16 services
| Return visit (30+ min) | 214 | $23,937 | $86 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 122 | $19,915 | $163 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 68 | $13,571 | $200 |
| New patient visit (30+ min) | 158 | $12,916 | $82 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 131 | $12,697 | $93 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 49 | $9,382 | $191 |
| Diagnostic exam of large bowel using a flexible endoscope | 51 | $7,833 | $151 |
| New patient visit (45+ min) | 53 | $5,738 | $108 |
| Short return visit (20+ min) | 66 | $4,114 | $56 |
| Biopsy of large bowel using a flexible endoscope | 24 | $3,114 | $130 |
| Biopsy of small bowel (except ileum) using an endoscope | 21 | $2,544 | $121 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,448 | $94 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $2,346 | $168 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,618 | $108 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,432 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $936 | $59 |
2018: 23 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 192 | $30,095 | $155 |
| Return visit (30+ min) | 152 | $16,848 | $80 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 77 | $15,486 | $201 |
| New patient visit (45+ min) | 133 | $14,970 | $113 |
| Biopsy of small bowel (except ileum) using an endoscope | 122 | $13,091 | $102 |
| Short return visit (20+ min) | 182 | $12,854 | $54 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 39 | $7,314 | $188 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 35 | $6,560 | $187 |
| Diagnostic exam of large bowel using a flexible endoscope | 41 | $5,966 | $146 |
| Biopsy of large bowel using a flexible endoscope | 46 | $5,717 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 59 | $4,528 | $57 |
| Diagnostic exam of small bowel (excluding lower small intestine) using an endoscope | 36 | $3,835 | $107 |
| New patient visit (60+ min) | 26 | $3,527 | $136 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,041 | $105 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 13 | $3,017 | $232 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,460 | $98 |
| Control of bleeding of first or second part of small bowel using an endoscope | 12 | $2,315 | $193 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $2,277 | $84 |
| New patient visit (30+ min) | 26 | $1,829 | $70 |
| Long return visit (40+ min) | 12 | $1,318 | $94 |
| Incision of pancreatic outlet using a flexible endoscope | 12 | $857 | $71 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 13 | $388 | $28 |
| Stool analysis for blood, by peroxidase activity | 12 | $54 | $4 |
2017: 20 services
| New patient visit (45+ min) | 147 | $16,378 | $111 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 102 | $15,860 | $153 |
| Return visit (30+ min) | 148 | $15,828 | $79 |
| New patient visit (60+ min) | 84 | $12,593 | $150 |
| Short return visit (20+ min) | 131 | $9,010 | $52 |
| Biopsy of small bowel (except ileum) using an endoscope | 86 | $8,718 | $99 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 44 | $8,430 | $192 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 37 | $6,559 | $177 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 30 | $5,470 | $176 |
| Biopsy of large bowel using a flexible endoscope | 36 | $4,143 | $115 |
| Control of bleeding of first or second part of small bowel using an endoscope | 15 | $3,728 | $186 |
| Long return visit (40+ min) | 27 | $2,951 | $109 |
| Diagnostic exam of large bowel using a flexible endoscope | 21 | $2,752 | $131 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $2,452 | $72 |
| Diagnostic exam of small bowel (excluding lower small intestine) using an endoscope | 18 | $1,902 | $106 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,195 | $92 |
| Return visit (30+ min) | 12 | $772 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $761 | $54 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 11 | $355 | $27 |
| Stool analysis for blood, by peroxidase activity | 26 | $114 | $4 |
2016: 17 services
| Return visit (30+ min) | 258 | $27,257 | $76 |
| New patient visit (45+ min) | 204 | $21,861 | $107 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 120 | $20,197 | $155 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 160 | $15,546 | $94 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 76 | $13,717 | $180 |
| Diagnostic exam of large bowel using a flexible endoscope | 48 | $6,963 | $145 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 23 | $4,380 | $190 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 38 | $4,002 | $98 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 14 | $3,155 | $197 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 16 | $3,043 | $190 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,903 | $56 |
| Short return visit (20+ min) | 46 | $2,706 | $58 |
| Biopsy of large bowel using a flexible endoscope | 25 | $2,461 | $98 |
| Injection beneath lining of large bowel using a flexible endoscope | 15 | $808 | $54 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 13 | $530 | $28 |
| Incision of pancreatic outlet using a flexible endoscope | 11 | $307 | $28 |
| Stool analysis for blood to screen for colon tumors | 20 | $87 | $4 |
2015: 15 services
| New patient visit (45+ min) | 302 | $36,060 | $119 |
| Return visit (30+ min) | 283 | $30,910 | $82 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 71 | $15,838 | $220 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 93 | $15,326 | $158 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 144 | $13,846 | $92 |
| Diagnostic exam of large bowel using a flexible endoscope | 57 | $9,810 | $172 |
| Biopsy of large bowel using a flexible endoscope | 41 | $6,884 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 46 | $5,510 | $58 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 16 | $3,352 | $210 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 12 | $2,379 | $183 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,045 | $102 |
| New patient visit (45+ min) | 12 | $1,042 | $87 |
| Short return visit (20+ min) | 15 | $532 | $35 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 12 | $412 | $29 |
| Stool analysis for blood to screen for colon tumors | 23 | $100 | $4 |
2014: 17 services
| New patient visit (45+ min) | 165 | $20,253 | $123 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 100 | $16,360 | $160 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 60 | $14,522 | $242 |
| Return visit (30+ min) | 141 | $14,426 | $85 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 111 | $12,162 | $102 |
| Short return visit (20+ min) | 154 | $10,606 | $53 |
| Diagnostic exam of large bowel using a flexible endoscope | 49 | $8,440 | $172 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 18 | $3,935 | $219 |
| Biopsy of large bowel using a flexible endoscope | 24 | $3,445 | $144 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $3,069 | $102 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 13 | $2,969 | $228 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 35 | $2,885 | $58 |
| New patient visit (45+ min) | 12 | $1,261 | $105 |
| Incision of pancreatic outlet using a flexible endoscope | 13 | $693 | $49 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 14 | $468 | $29 |
| Injection beneath lining of large bowel using a flexible endoscope | 12 | $283 | $24 |
| Stool analysis for blood to screen for colon tumors | 22 | $92 | $4 |
2013: 14 services
| Short return visit (20+ min) | 252 | $20,372 | $54 |
| New patient visit (45+ min) | 153 | $18,729 | $122 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 105 | $16,303 | $151 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 64 | $15,328 | $240 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 115 | $13,049 | $110 |
| Diagnostic exam of large bowel using a flexible endoscope | 50 | $8,758 | $172 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 15 | $6,367 | $335 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 51 | $6,158 | $56 |
| Biopsy of large bowel using a flexible endoscope | 30 | $4,842 | $156 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $3,591 | $109 |
| Return visit (30+ min) | 23 | $2,398 | $86 |
| Incision of pancreatic outlet using a flexible endoscope | 20 | $1,288 | $64 |
| Review by radiologist of image from tube placement into bile duct using an endoscope | 16 | $644 | $28 |
| Stool analysis for blood to screen for colon tumors | 15 | $66 | $4 |
Medicaid work
$18,495 in 2024
Medicaid paid $18,495 for 417 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| 1ST HOSP IP/OBS HIGH 75 | 251 | $12,976 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 126 | $2,373 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 28 | $1,629 |
| Upper gastrointestinal endoscopy with biopsy | 12 | $1,517 |
| 2024 | 417 | 4 | 27 | $18,495 |
| 2023 | 551 | 3 | 37 | $25,393 |
| 2022 | 50 | 1 | 17 | $3,551 |
See the largest Medicaid services in earlier years
2023
| 1ST HOSP IP/OBS HIGH 75 | 299 | $16,522 |
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 201 | $5,701 |
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 51 | $3,169 |
2022
| 1ST HOSP IP/OBS HIGH 75 | 50 | $3,551 |
Drugs they prescribed that Part D paid
$304,491
Pharmacies billed $304,491 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
493 generic and 119 brand-name prescriptions · $304,491 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sod Sulf-Potass Sulf-Mag Sulf | 164 | $10,056 | $61 |
| Alosetron | 11 | $9,175 | $834 |
| Linzess | 11 | $5,596 | $509 |
| Clenpiq | 29 | $5,038 | $174 |
| Dexlansoprazole Dr | 11 | $4,706 | $428 |
See all 11 drugs
| Sod Sulf-Potass Sulf-Mag Sulf | 164 | $10,056 | $61 |
| Alosetron | 11 | $9,175 | $834 |
| Linzess | 11 | $5,596 | $509 |
| Clenpiq | 29 | $5,038 | $174 |
| Dexlansoprazole Dr | 11 | $4,706 | $428 |
| Lansoprazole | 17 | $1,745 | $103 |
| Pantoprazole | 143 | $1,693 | $12 |
| Gavilyte-G | 35 | $476 | $14 |
| Diphenoxylate-Atropine | 21 | $387 | $18 |
| Peg-3350 and Electrolytes | 25 | $374 | $15 |
| Omeprazole | 23 | $307 | $13 |
Year by year
| 2024 | 612 | 336 | None | 19% | $304,491 |
| 2023 | 502 | 274 | None | 21% | $220,874 |
| 2022 | 513 | 271 | None | 29% | $61,930 |
| 2021 | 565 | 284 | None | 33% | $77,117 |
| 2020 | 612 | 262 | None | 15% | $74,081 |
| 2019 | 904 | 354 | 2% (15) | 28% | $140,006 |
| 2018 | 1,484 | 457 | None | 28% | $461,345 |
| 2017 | 1,390 | 406 | None | 30% | $378,116 |
| 2016 | 1,397 | 385 | None | 31% | $214,855 |
| 2015 | 1,218 | 399 | None | 40% | $175,804 |
| 2014 | 1,002 | 268 | None | 32% | $100,891 |
| 2013 | 822 | 227 | None | None | $109,308 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Pentasa | 12 | $14,562 | $1,214 |
| Dexlansoprazole Dr | 14 | $5,810 | $415 |
| Clenpiq | 29 | $5,137 | $177 |
| Sutab | 14 | $2,404 | $172 |
| Sod Sulf-Potass Sulf-Mag Sulf | 31 | $2,340 | $75 |
| Pantoprazole | 92 | $1,756 | $19 |
| Gavilyte-G | 107 | $1,707 | $16 |
| Omeprazole | 38 | $869 | $23 |
| Dicyclomine | 13 | $610 | $47 |
| Peg-3350 and Electrolytes | 14 | $212 | $15 |
2022: 10 drugs
| Alosetron | 12 | $8,459 | $705 |
| Mesalamine Er | 12 | $7,632 | $636 |
| Linzess | 12 | $6,308 | $526 |
| Suprep | 55 | $6,191 | $113 |
| Peg 3350-Electrolyte | 83 | $1,506 | $18 |
| Pantoprazole | 80 | $1,423 | $18 |
| Omeprazole | 47 | $691 | $15 |
| Dicyclomine | 16 | $663 | $41 |
| Gavilyte-G | 32 | $494 | $15 |
| Peg-3350 and Electrolytes | 12 | $154 | $13 |
2021: 9 drugs
| Suprep | 131 | $14,520 | $111 |
| Alosetron | 13 | $10,209 | $785 |
| Mesalamine Er | 12 | $9,844 | $820 |
| Mesalamine | 11 | $8,101 | $736 |
| Omeprazole | 93 | $1,491 | $16 |
| Pantoprazole | 86 | $1,360 | $16 |
| Peg 3350-Electrolyte | 43 | $768 | $18 |
| Dicyclomine | 16 | $635 | $40 |
| Metronidazole | 11 | $140 | $13 |
2020: 12 drugs
| Alosetron | 13 | $17,853 | $1,373 |
| Mesalamine Er | 14 | $10,906 | $779 |
| Suprep | 50 | $5,272 | $105 |
| Lansoprazole | 20 | $4,807 | $240 |
| Budesonide Ec | 13 | $4,475 | $344 |
| Sucralfate | 20 | $1,794 | $90 |
| Omeprazole | 115 | $1,524 | $13 |
| Pantoprazole | 111 | $1,452 | $13 |
| Gavilyte-C | 69 | $876 | $13 |
| Dicyclomine | 18 | $703 | $39 |
| Gavilyte-G | 31 | $403 | $13 |
| Metoclopramide | 16 | $81 | $5 |
2019: 18 drugs
| Alosetron | 12 | $23,912 | $1,993 |
| Apriso | 15 | $14,870 | $991 |
| Suprep | 128 | $13,022 | $102 |
| Linzess | 16 | $11,151 | $697 |
| Mesalamine | 16 | $9,302 | $581 |
| Dexilant | 16 | $6,664 | $417 |
| Omeprazole | 197 | $3,131 | $16 |
| Pantoprazole | 112 | $1,580 | $14 |
| Lansoprazole | 11 | $1,316 | $120 |
| Esomeprazole Magnesium | 16 | $1,225 | $77 |
| Gavilyte-G | 67 | $905 | $14 |
| Sucralfate | 16 | $762 | $48 |
| Lidocaine Hcl Viscous | 31 | $347 | $11 |
| Gavilyte-C | 11 | $227 | $21 |
| Dicyclomine | 20 | $154 | $8 |
| Metoclopramide | 24 | $147 | $6 |
| Ranitidine | 25 | $142 | $6 |
| Acetaminophen-Codeine | 15 | $106 | $7 |
2018: 30 drugs
| Creon | 22 | $32,006 | $1,455 |
| Mesalamine | 46 | $29,716 | $646 |
| Linzess | 38 | $19,701 | $518 |
| Apriso | 34 | $17,862 | $525 |
| Budesonide Ec | 25 | $15,884 | $635 |
| Dexilant | 43 | $13,991 | $325 |
| Zenpep | 11 | $12,529 | $1,139 |
| Alosetron | 12 | $7,308 | $609 |
| Carafate | 15 | $5,848 | $390 |
| Suprep | 59 | $5,544 | $94 |
| Movantik | 15 | $5,369 | $358 |
| Omeprazole | 305 | $4,910 | $16 |
| Rabeprazole | 19 | $4,799 | $253 |
| Esomeprazole Magnesium | 28 | $4,166 | $149 |
| Ursodiol | 27 | $3,894 | $144 |
| Pantoprazole | 168 | $2,235 | $13 |
| Mercaptopurine | 11 | $2,190 | $199 |
| Gavilyte-G | 124 | $1,447 | $12 |
| Ranitidine | 55 | $867 | $16 |
| Lansoprazole | 19 | $814 | $43 |
| Sulfasalazine | 22 | $649 | $29 |
| Peg-3350 and Electrolytes | 46 | $491 | $11 |
| Metoclopramide | 51 | $473 | $9 |
| Sucralfate | 14 | $472 | $34 |
| Peg 3350-Electrolyte | 12 | $358 | $30 |
| Prednisone | 23 | $271 | $12 |
| Ondansetron Odt | 12 | $206 | $17 |
| Metronidazole | 11 | $171 | $16 |
| Dicyclomine | 28 | $141 | $5 |
| Amlodipine Besylate | 12 | $34 | $3 |
2017: 29 drugs
| Xifaxan | 18 | $36,877 | $2,049 |
| Alosetron | 13 | $30,528 | $2,348 |
| Linzess | 45 | $25,443 | $565 |
| Budesonide Ec | 27 | $20,631 | $764 |
| Mesalamine | 28 | $20,415 | $729 |
| Dexilant | 51 | $18,632 | $365 |
| Apriso | 25 | $14,113 | $565 |
| Creon | 19 | $13,741 | $723 |
| Lialda | 14 | $9,287 | $663 |
| Esomeprazole Magnesium | 37 | $6,956 | $188 |
| Ursodiol | 31 | $5,029 | $162 |
| Omeprazole | 288 | $4,388 | $15 |
| Amitiza | 12 | $4,284 | $357 |
| Carafate | 12 | $3,883 | $324 |
| Suprep | 25 | $2,202 | $88 |
| Rabeprazole | 14 | $2,169 | $155 |
| Pantoprazole | 124 | $1,699 | $14 |
| Lansoprazole | 23 | $1,373 | $60 |
| Gavilyte-G | 103 | $1,362 | $13 |
| Azathioprine | 17 | $929 | $55 |
| Spironolactone | 27 | $677 | $25 |
| Peg-3350 and Electrolytes | 52 | $594 | $11 |
| Sulfasalazine | 17 | $539 | $32 |
| Sucralfate | 24 | $496 | $21 |
| Metoclopramide | 61 | $451 | $7 |
| Ranitidine | 23 | $278 | $12 |
| Dicyclomine | 27 | $196 | $7 |
| Metronidazole | 12 | $133 | $11 |
| Furosemide | 13 | $50 | $4 |
2016: 28 drugs
| Asacol Hd | 24 | $25,758 | $1,073 |
| Pentasa | 18 | $25,585 | $1,421 |
| Linzess | 32 | $15,725 | $491 |
| Apriso | 28 | $15,500 | $554 |
| Lialda | 30 | $15,240 | $508 |
| Mesalamine | 13 | $13,973 | $1,075 |
| Dexilant | 47 | $13,390 | $285 |
| Budesonide Ec | 11 | $10,692 | $972 |
| Esomeprazole Magnesium | 46 | $9,201 | $200 |
| Nexium | 21 | $8,673 | $413 |
| Carafate | 24 | $5,480 | $228 |
| Omeprazole | 310 | $4,886 | $16 |
| Ursodiol | 18 | $3,708 | $206 |
| Rabeprazole | 25 | $2,964 | $119 |
| Suprep | 31 | $2,549 | $82 |
| Lansoprazole | 23 | $1,738 | $76 |
| Pantoprazole | 158 | $1,622 | $10 |
| Gavilyte-G | 77 | $976 | $13 |
| Azathioprine | 17 | $944 | $56 |
| Peg-3350 and Electrolytes | 76 | $899 | $12 |
| Spironolactone | 32 | $677 | $21 |
| Metoclopramide | 74 | $503 | $7 |
| Sulfasalazine | 12 | $388 | $32 |
| Dicyclomine | 39 | $323 | $8 |
| Sucralfate | 16 | $264 | $17 |
| Metronidazole | 12 | $138 | $11 |
| Ranitidine | 11 | $78 | $7 |
| Furosemide | 12 | $46 | $4 |
2015: 22 drugs
| Asacol Hd | 27 | $26,582 | $985 |
| Pentasa | 11 | $18,518 | $1,683 |
| Dexilant | 78 | $17,938 | $230 |
| Nexium | 42 | $16,104 | $383 |
| Apriso | 31 | $14,853 | $479 |
| Linzess | 37 | $12,454 | $337 |
| Lialda | 25 | $9,926 | $397 |
| Carafate | 19 | $6,455 | $340 |
| Esomeprazole Magnesium | 13 | $3,248 | $250 |
| Omeprazole | 248 | $2,916 | $12 |
| Rabeprazole | 17 | $1,957 | $115 |
| Pantoprazole | 112 | $1,458 | $13 |
| Peg-3350 and Electrolytes | 110 | $1,286 | $12 |
| Lansoprazole | 24 | $1,251 | $52 |
| Suprep | 13 | $1,053 | $81 |
| Gavilyte-G | 78 | $957 | $12 |
| Azathioprine | 25 | $728 | $29 |
| Sulfasalazine | 15 | $465 | $31 |
| Metoclopramide | 65 | $401 | $6 |
| Ondansetron Odt | 12 | $186 | $16 |
| Dicyclomine | 30 | $179 | $6 |
| Spironolactone | 11 | $177 | $16 |
2014: 19 drugs
| Dexilant | 94 | $20,290 | $216 |
| Nexium | 32 | $13,099 | $409 |
| Linzess | 18 | $6,423 | $357 |
| Lialda | 16 | $6,130 | $383 |
| Amitiza | 13 | $4,031 | $310 |
| Creon | 23 | $3,841 | $167 |
| Omeprazole | 226 | $2,958 | $13 |
| Lansoprazole | 32 | $1,860 | $58 |
| Peg-3350 and Electrolytes | 78 | $1,047 | $13 |
| Levofloxacin | 14 | $788 | $56 |
| Sulfasalazine | 17 | $759 | $45 |
| Pantoprazole | 56 | $645 | $12 |
| Gavilyte-G | 47 | $589 | $13 |
| Azathioprine | 29 | $503 | $17 |
| Sulfazine | 11 | $379 | $34 |
| Metoclopramide | 58 | $355 | $6 |
| Dicyclomine | 32 | $232 | $7 |
| Spironolactone | 12 | $206 | $17 |
| Ondansetron Odt | 11 | $185 | $17 |
2013: 17 drugs
| Dexilant | 120 | $22,189 | $185 |
| Budesonide Ec | 21 | $21,282 | $1,013 |
| Nexium | 25 | $11,672 | $467 |
| Amitiza | 22 | $5,987 | $272 |
| Asacol | 11 | $5,069 | $461 |
| Lialda | 12 | $4,657 | $388 |
| Carafate | 15 | $3,194 | $213 |
| Lansoprazole | 26 | $3,026 | $116 |
| Omeprazole | 124 | $2,226 | $18 |
| Pantoprazole | 63 | $1,132 | $18 |
| Peg-3350 and Electrolytes | 70 | $1,008 | $14 |
| Colestipol | 11 | $776 | $71 |
| Polyethylene Glycol 3350 | 13 | $572 | $44 |
| Sulfasalazine | 11 | $454 | $41 |
| Metoclopramide | 58 | $383 | $7 |
| Ondansetron | 12 | $365 | $30 |
| Gavilyte-G | 20 | $297 | $15 |
Money from drug and device companies
$2,048 in 2025
| 2025 | 10 | 23 | $1,500 | $2,048 |
| 2024 | 6 | 20 | None | $492 |
| 2023 | 6 | 29 | None | $915 |
| 2022 | 7 | 29 | None | $843 |
| 2021 | 9 | 36 | None | $710 |
| 2020 | 10 | 22 | None | $698 |
| 2019 | 10 | 33 | $21 | $569 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Olympus Medical Systems | Evis Exera III Duodenovideoscope | $1,500 | 1 payment
|
| Abbvie | Rinvoq | $244 | 9 payments
|
| Medtronic | Endoflip | $70 | 2 payments
|
| Aimmune Therapeutics | Zenpep | $54 | 3 payments
|
| Pfizer | Xeljanz | $41 | 2 payments
|
| Celltrion USA | Vegzelma | $38 | 2 payments
|
See all 23 published payments
| Abbvie | Meals · 2025-12-15 | Rinvoq | $32 |
| Medtronic | Meals · 2025-11-20 | Manoscan | $28 |
| Abbvie | Meals · 2025-11-18 | Skyrizi | $29 |
| Olympus Medical Systems | Consulting · 2025-11-02 | Evis Exera III Duodenovideoscope | $1,500 |
| Celltrion USA | Meals · 2025-10-22 | Vegzelma | $19 |
| Abbvie | Meals · 2025-10-20 | Rinvoq | $24 |
| Regeneron Healthcare Solutions | Meals · 2025-09-24 | Dupixent | $32 |
| Abbvie | Meals · 2025-08-25 | Rinvoq | $29 |
| Pfizer | Meals · 2025-08-18 | Velsipity | $18 |
| Abbvie | Meals · 2025-06-30 | Rinvoq | $22 |
| Getinge USA Sales | Meals · 2025-05-23 | Cardiohelp | $21 |
| Abbvie | Meals · 2025-05-12 | Rinvoq | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-05-12 | Xifaxan | $21 |
| Aimmune Therapeutics | Meals · 2025-05-02 | Zenpep | $20 |
| Abbvie | Meals · 2025-04-14 | Skyrizi | $27 |
| Pfizer | Meals · 2025-04-07 | Xeljanz | $23 |
| Medtronic | Meals · 2025-03-17 | Endoflip | $42 |
| Abbvie | Meals · 2025-03-03 | Rinvoq | $32 |
| Aimmune Therapeutics | Meals · 2025-02-18 | Zenpep | $19 |
| Celltrion USA | Meals · 2025-02-13 | Vegzelma | $19 |
| Abbvie | Meals · 2025-02-03 | Rinvoq | $22 |
| Olympus America | Meals · 2025-01-22 | Endoclot Sis | $28 |
| Aimmune Therapeutics | Meals · 2025-01-18 | Zenpep | $15 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $492
| Abbvie | Rinvoq | $316 | 14 payments
|
| Boston Scientific | Compliance Endokit | $87 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $29 | 1 payment
|
| Janssen Biotech | Tremfya | $20 | 1 payment
|
| Aimmune Therapeutics | Zenpep | $20 | 1 payment
|
| Phathom Pharmaceuticals | Voquezna | $20 | 1 payment
|
2023: $915
| Boston Scientific | Orcapod | $430 | 6 payments
|
| AbbVie | Rinvoq | $343 | 17 payments
|
| Nestle Healthcare Nutrition | Zenpep | $65 | 3 payments
|
| Pfizer | Xeljanz | $27 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $26 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $24 | 1 payment
|
2022: $843
| Abbvie | Rinvoq | $318 | 21 payments
|
| Boston Scientific | Advanix Biliary | $305 | 3 payments
|
| Olympus America | Endocuff Vision | $149 | 1 payment
|
| Nestle HealthCare Nutrition | Zenpep | $25 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $24 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $19 | 1 payment
|
| Ambu | None | $4 | 1 payment
|
2021: $710
| AbbVie | Humira | $200 | 9 payments
|
| Janssen Biotech | Stelara | $157 | 13 payments
|
| Nestle HealthCare Nutrition | Zenpep | $139 | 6 payments
|
| Boston Scientific | Resolution Clip | $74 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $43 | 2 payments
|
| Ambu | None | $30 | 1 payment
|
| Amgen | Avsola | $26 | 1 payment
|
| Intra-Sana Laboratories | Reltone 200 Mg | $22 | 1 payment
|
| Daiichi Sankyo | Injectafer | $18 | 1 payment
|
2020: $698
| Ambu | None | $164 | 1 payment
|
| Boston Scientific | General - Endochoice | $150 | 3 payments
|
| Janssen Biotech | Stelara | $71 | 3 payments
|
| Allergan | Linzess | $65 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $65 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $54 | 3 payments
|
| Daiichi Sankyo | Injectafer | $42 | 2 payments
|
| AbbVie | Humira | $38 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $34 | 2 payments
|
| Nestle HealthCare Nutrition | Zenpep | $17 | 1 payment
|
2019: $569
| Allergan | Linzess | $126 | 9 payments
|
| Takeda Pharmaceuticals U.S.A. | Motegrity | $109 | 7 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $75 | 4 payments
|
| AbbVie | Humira | $74 | 4 payments
|
| Pfizer | Xeljanz | $41 | 2 payments
|
| Merck Sharp & Dohme | Dificid | $36 | 2 payments
|
| Daiichi Sankyo | Injectafer | $35 | 2 payments
|
| Ironwood Pharmaceuticals | Linzess | $27 | 1 payment
|
| Shionogi | Mulpleta | $25 | 1 payment
|
| Intercept Pharmaceuticals | Ocaliva | $21 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1386613206
- Licence
- CA A87308, MT 98403California A87308: Current · expires 2027-08-31
- Group
- Emergency and Acute Care Medical Corporation · Banaie Medical Corporation · Providence Medical Foundation
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A873080
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 8860 Center Drive, Suite 420, La Mesa, CA, 91942
- NPI first listed
- 2006-03-14
- NPI last updated
- 2023-03-21
- NPI record certified
- 2023-03-21
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1401 25th St S, Great Falls, MT, 59405
This office lists an electronic records connection.